Clinical Trial Update: Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase II clinical trial is evaluating the combination of utidelone and fruquintinib for platinum-resistant recurrent ovarian cancer; the study is not yet recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Fruquintinib (fruquintinib)
• Utidelone (utidelone)

Snippet

Sponsor: Fudan University | Conditions: Platinum Resistant Ovarian Cancer | Phase 2 | Status: NOT_YET_RECRUITING